Biogen Inc. is a global biotechnology company headquartered in Cambridge, Massachusetts, dedicated to discovering, developing, and delivering therapies for neurological and neurodegenerative diseases, operating within the Healthcare sector's Drug Manufacturers industry. The company's focus includes treatments for conditions such as multiple sclerosis and spinal muscular atrophy, alongside a pipeline targeting Alzheimer's and Parkinson's diseases. Biogen's recent quarterly performance shows a mixed but generally strong trend against analyst expectations. Notably, Q2 2025 saw a significant earnings beat with actual EPS of $5.47 against an estimate of $3.88, and Q3 2025 also beat estimates with $4.81 actual EPS versus $3.88 estimated. This follows beats in Q4 2024 ($3.44 actual vs $3.36 est) and Q1 2025 ($3.02 actual vs $2.95 est). Revenue trends have also shown growth, with Q2 2025 revenue reaching $2.65 billion and Q3 2025 at $2.53 billion, though Q4 2025 revenue of $2.28 billion missed its estimate of $2.25 billion. Historically, Biogen has demonstrated a strong track record of exceeding earnings expectations, with an average surprise of over 23% in the last two reported quarters, supported by positive Zacks Earnings ESP and Rank. Recent news highlights a significant collaboration with Alloy Therapeutics to advance oligonucleotide therapeutics and the integration of the Apellis Pharmaceuticals acquisition, which adds new drugs and expertise to its rare disease portfolio. Analysts have adjusted price targets, with some lowering them while maintaining positive ratings, indicating ongoing confidence. Investors will be watching for updates on clinical trial progress, the impact of the Apellis acquisition on future earnings, and the company's performance in the growing idiopathic membranous nephropathy market.
